Subcutaneous alemtuzumab in patients with refractory/relapsed B-CLL after a fludarabine-based regimen.

被引：0
|
作者：
Bezares, R.
Stemmelin, G.
Argentieri, D.
Lanari, E.
Guy-Garay, E.
Campestri, R.
Bartomioli, M.
Garcia, J.
Giralt, S.
Milone, G.
机构：
[1] Hosp Gen Agudos, Buenos Aires, DF, Argentina
[2] Hosp Britan, Buenos Aires, DF, Argentina
[3] Sanatorio Mitre, Buenos Aires, DF, Argentina
[4] Ctr Med Corrientes, Buenos Aires, DF, Argentina
[5] CEMIC, Buenos Aires, DF, Argentina
[6] Hosp Pena Bahia Blanca, Buenos Aires, DF, Argentina
[7] Hosp Privado Cordova, Cordova, Argentina
[8] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Fundaleu, Buenos Aires, DF, Argentina
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360S / 360S
页数：1
相关论文
共 50 条
  • [41] FLUDARABINE AND PREDNISONE IN PRETREATED AND REFRACTORY B-CHRONIC LYMPHOCYTIC-LEUKEMIA (B-CLL) IN ADVANCED STAGES
    DEROSSI, G
    MAURO, FR
    CARUSO, R
    MONARCA, B
    MANDELLI, F
    HAEMATOLOGICA, 1993, 78 (03) : 167 - 171
  • [42] T-cell function in patients with B-cell chronic lymphocytic leukemia (B-CLL) following alemtuzumab (Campath®) or fludarabine treatment.
    Kiaii, S
    Mozaffari, F
    Lundin, J
    Rezvany, R
    Chudhury, A
    Mellstedt, H
    Osterborg, A
    BLOOD, 2004, 104 (11) : 689A - 689A
  • [43] Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL.
    Wierda, William G.
    O'Brien, Susan
    Faderl, Stefan
    Ferrajoli, Alessandra
    Ravandi-Kashani, Farhad
    Cortes, Jorge
    Giles, Francis
    Andreeff, Michael
    Koller, Charles Asa
    Lerner, Susan
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2006, 108 (11) : 14A - 14A
  • [44] Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis
    Fernando Bezares, Raimundo
    Stemelin, German
    Diaz, Alicia
    Argentieri, Daniel
    Lanari Zubiaur, Emilio
    Garay, Guy
    Bartomioli, Miguel
    Ryser, Ricardo
    Milone, Gustavo
    LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1936 - 1941
  • [45] Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia
    Park, Hyunkyung
    Youk, Jeonghwan
    Kim, Inho
    Yoon, Sung-Soo
    Park, Seonyang
    Lee, Jeong-Ok
    Bang, Soo-Mee
    Koh, Youngil
    ANNALS OF HEMATOLOGY, 2016, 95 (11) : 1777 - 1786
  • [46] Outcome of patients with refractory/relapsed AML salvaged with the MEC (Mitoxantrone Etoposide Cytarabine) regimen.
    Castagnola, C
    Alessandrino, EP
    Pagnucco, G
    Bernasconi, P
    Lunghi, M
    Colombo, A
    Brusamolino, E
    Bonfichi, M
    Corso, A
    Lazzarino, M
    Bernasconi, C
    BLOOD, 2000, 96 (11) : 210B - 210B
  • [47] Analysis of minimal residual disease (MRD) from the phase 2 multicenter study of subcutaneous (SC) alemtuzumab combined with fludarabine for treatment of relapsed/refractory B-cell chronic lymphocytic leukemia (CLL).
    Flowers, Christopher
    Rosenthal, Hilary
    Brown, Jennifer
    Stock, Wendy
    Katzen, Harvey
    Lakhanpal, Shailendra
    Jaye, David
    BLOOD, 2007, 110 (11) : 915A - 915A
  • [48] Phase II Trial of Subcutaneous Alemtuzumab in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 202 - 203
  • [49] Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers
    Stilgenbauer, Stephan
    Zenz, Thorsten
    Winkler, Dirk
    Buehler, Andreas
    Groner, Sija
    Busch, Raymonde
    Hensel, Manfred
    Duehrsen, Ulrich
    Finke, Juergen
    Dreger, Peter
    Jaeger, Ulrich
    Lengfelder, Eva
    Truemper, Lorenz H.
    Soeling, Ulrike
    Schlag, Rudolf
    Hallek, Michael
    Doehner, Hartmut
    BLOOD, 2008, 112 (11) : 127 - 127
  • [50] Clinical outcomes in patients with relapsed/refractory acute leukemia treated with FLAG-IDA regimen.
    Basquiera, Ana L.
    Prates, M. Virginia
    Sturich, Ana Gabriela
    Berretta, Adriana R.
    Milone, Jorge
    Garcia, Juan
    BLOOD, 2006, 108 (11) : 220B - 220B
12345